News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Subscribe To Our Newsletter & Stay Updated
